Skip to main content

Table 2B Relative use of LHRH agonist (Goserelin) in premenopausal patients in addition to other endocrine agents

From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

Patients with Goserelin/Total patients treated each line (%)

1st line 31/223 (13.9)

2nd line 5/115 (4.3)

3rd line 2/71 (2.8)

4th line 2/32 (6.2)

5th line 0/8 (0)

Tamoxifen

12 (5.4)

None

None

1 (3.1)

None

Anastrozole

19 (8.5)

3 (2.6)

None

None

None

Exemestane

None

2 (1.7)

2 (2.8)

1 (3.1)

None